Aspira Pathlab Open Offer Details

Aspira Pathlab & Diagnostics Ltd is undergoing an open offer to purchase up to 26,76,180 equity shares at ₹55 per share. This offer, valued at a maximum of ₹14.72 crore, seeks to acquire a 26% stake in the diagnostics company.

Open Offer Specifics

An open offer has been made to acquire up to 26,76,180 equity shares of Aspira Pathlab & Diagnostics Limited at ₹55 per share. The total value of the offer is capped at approximately ₹14.72 crore.

The period for shareholders to tender their shares is scheduled from April 15, 2026, to April 28, 2026. The initial public announcement for this offer was made on September 26, 2025.

Why This Offer Matters

This open offer presents an exit opportunity for existing public shareholders at a set price. It indicates a significant shift in shareholding, potentially leading to a change in control or strategic direction. However, the acquirers have stated that no major changes to the company's business are currently planned.

About Aspira Pathlab & Diagnostics

Established in 1973, Aspira Pathlab & Diagnostics Limited operates diagnostic centers across Mumbai. The company provides pathology and radiology services and aims to expand its reach and integrate new technologies to enhance customer experience.

The current offer is made in compliance with SEBI regulations for substantial acquisitions. Recent administrative changes include the resignation of the company's Company Secretary cum Compliance Officer in March 2026.

Key Actions for Shareholders

• Tender Shares: Public shareholders have the option to sell their shares at ₹55 per share.
• Premium Exit: The offer provides a premium exit opportunity above recent market conditions.
• Acquirer Intent: The acquirers plan to maintain existing business operations with no significant alterations.
• Active Participation: Shareholders must actively participate by tendering their shares within the offer period to benefit from the ₹55 price.
• Document Submission: Ensure timely submission of all required documents for successful acceptance of the offer.

Potential Risks

• Approval Contingency: The open offer could be withdrawn if necessary statutory or regulatory approvals are not obtained.
• Payment Delays: Delays in payment or the return of shares might occur if approval processes are not completed on time.
• Deal Conditions: The successful completion of the offer depends on meeting all conditions outlined in the acquisition agreement.

Industry Context

Aspira Pathlab operates within India's growing diagnostics sector. Key players in this market include Dr Lal Pathlabs, Metropolis Healthcare, Vijaya Diagnostics, and Thyrocare Technologies. The sector is experiencing growth driven by increased demand for preventive healthcare and a rise in lifestyle-related diseases.

Financial Snapshot

• Revenue (FY 2024-25): Aspira Pathlab & Diagnostics Ltd reported a revenue of ₹22.4 crore for the financial year ending March 31, 2025.
• Paid-up Capital (as of March 31, 2025): The company's paid-up capital stood at ₹15.8 crore.

What to Watch Next

• Shareholder Participation: Keep an eye on the number of shares tendered during the offer period (April 15-28, 2026).
• Regulatory Approvals: Track the status of any required statutory or regulatory clearances.
• Offer Status: Watch for announcements regarding any potential extension or withdrawal of the offer.
• Payment Timeline: Note that payment for accepted shares is expected within 10 working days after the offer closes.